Fulzerasib Tablets (Dupert®) – 150?mg × 112 Tablets per Box Price comparison

评级 5.00 / 5，已有 1 位客户进行了评价

$1.00

Fulzerasib (Dupert®) is an orally active KRAS G12C inhibitor, conditionally approved in China for advanced non–small-cell lung cancer (NSCLC) with KRAS G12C mutation. Manufactured by CindaBio, NMPA approved under H20240035 (drug code: 86985200000015). Strictly for laboratory research use only—NOT for clinical or human consumption.

Compare

描述

Contents hide

1 Fulzerasib Tablets Product Specifications

2 Fulzerasib Tablets Overview & Mechanism

3 Fulzerasib Tablets Research & Clinical Data

4 Fulzerasib Tablets Research Applications

5 Handling & Storage

6 References

Fulzerasib Tablets Product Specifications

Attribute	Details
Product Name	Fulzerasib Tablets (Dupert®)
Dosage & Quantity	150?mg per tablet × 112 tablets per box
Formulation	Film-coated tablet
Chinese Approval No.	NMPA H20240035
Product Code	86985200000015
Manufacturer	(CindaBio)
Intended Use	Laboratory research only; not for human use

Fulzerasib Tablets Overview & Mechanism

Fulzerasib is a covalent KRAS G12C inhibitor, irreversibly binding to the mutant cysteine 12 residue. It blocks KRAS-driven signaling (RAF–MEK–ERK, PI3K–AKT), inducing tumor cell growth arrest and apoptosis—and may also modulate the tumor immune microenvironment pharmaceutical-technology.com+15cancernetwork.com+15pubmed.ncbi.nlm.nih.gov+15synapse.patsnap.com.

Fulzerasib Tablets Research & Clinical Data

China Conditional Approval (Aug 2024) for KRAS G12C+ advanced NSCLC after ?1 prior treatment
Phase II (NCT05005234): ORR 49.1%, DCR 90.5%, median PFS 9.7?mo; median OS not reached in 116 patients
Combination Study (KROCUS): Fulzerasib + cetuximab showed ORR ~80% and DCR ~100%, including CNS activity in brain metastases

Fulzerasib Tablets Research Applications

Perfect for:

KRAS G12C molecular studies in vitro/in vivo
NSCLC tumor biology and resistance pathways
Signal-transduction profiling and biomarker investigations
Combo therapy research (e.g., with EGFR inhibitors)

Handling & Storage

Store at room temperature (20–25?°C); avoid light and moisture.
Handle with standard lab PPE; avoid ingestion or inhalation.
Packaging: Sealed blister box—inspect integrity before use.

References

China NMPA approval (Aug 2024) firstwordpharma.com+9cancernetwork.com+9english.nmpa.gov.cn+9
Phase II trial results delveinsight.com+4jto.org+4firstwordpharma.com+4
KRAS inhibition mechanism genfleet.com+13synapse.patsnap.com+13oncpracticemanagement.com+13
Fulzerasib + cetuximab combo data cancernetwork.com+15onclive.com+15jto.org+15